Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197461 | 0.81 | L3MBTL1 (0.43) | L3MBTL1NOTUMALDH1A1MAPTHPGD | |
| SCHEMBL2657681 | 0.76 | L3MBTL1 (0.48) | L3MBTL1NOTUMALDH1A1MAPTKCNN4 | |
| SCHEMBL5549540 | 0.69 | L3MBTL1 (0.52) | L3MBTL1NOTUMALDH1A1MAPTHPGD | |
| SCHEMBL28463471 | 0.69 | GABRA2 (0.44) | L3MBTL1NOTUMALDH1A1MAPTP2RX7 | |
| SCHEMBL5781675 | 0.67 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL1197773 | 0.66 | ITGB2 (0.36) | L3MBTL1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL1197768 | 0.66 | ITGB2 (0.36) | L3MBTL1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL9427590 | 0.66 | — | — | |
| SCHEMBL8705898 | 0.66 | NOTUM (0.48) | NOTUMALDH1A1MAPTHPGDHTT | |
| SCHEMBL8327571 | 0.66 | NOTUM (0.48) | NOTUMALDH1A1MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1209362-C | Tetrazolyl-phenyl acetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-07-06 | — | — | CN | disclosed |
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| CN-1466584-A | Tetrazolyl-phenyl acetamide glucokinase activators | - | 2004-01-07 | — | — | CN | disclosed |
| EP-1311504-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-6441180-B1 | TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-05-30 | — | — | US | disclosed |
| US-6388088-B1 | ANTIDIABETIC AGENTS | HOFFMAN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369232-B1 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002014312-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | L3MBTL1 3867/4885NOTUM 1489/4885ALDH1A1 2457/4885 |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | L3MBTL1 3867/4885NOTUM 1489/4885ALDH1A1 2457/4885 |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | GCKR, GCK, PFKL | L3MBTL1 4075/4885NOTUM 1459/4885ALDH1A1 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.